Debra Feldman announced as Vice President, Head of Regulatory at Dyne Therapeutics

pharmafile | May 15, 2020 | Appointment | Research and Development  

Dyne Therapeutics has announced the appointment of Debra Feldman as their new Vice President, Head of Regulatory.

Feldman said on her appointment: “People with serious muscle diseases and their families urgently need therapies with the potential to address the disease burden they face. I am thrilled to be joining Dyne at a pivotal time in our development, as we advance rapidly toward the clinic.”

Feldman has more than 20 year of regulatory experience in biotech and life science. Prior to joining Dyne, she led the led regulatory organisation at Sage Therapeutics and oversaw regulatory initiatives across a pipeline of products that treated neurological and psychiatric disorders. She also led the company through the regulatory approval of ZULRESSO, which was the first and only treatment for postpartum depression.

In terms of education, Feldman holds a BA from University of Massachusetts, a degree in nutritional science from Simmons College and a Master of Public Health from Boston University.

Joshua Brumm, the President and Chief Executive Officer of Dyne, commented on her appointment and said: “Debra brings significant experience in global regulatory strategy to the Dyne team, including substantial knowledge of the rare disease and neuromuscular spaces. Her expertise in navigating regulatory pathways will be invaluable as we rapidly progress our programs toward clinical development, with the aim of developing life-saving therapies for serious muscle diseases.”

Conor Kavanagh

Related Content

No items found

Latest content